NURIX THERAPEUTICS INC (NRIX)
Health Care · biotechnology · NASDAQ
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate bexobrutideg in CLL and partnerships spanning Roche, Gilead, and Sanofi.
What NURIX THERAPEUTICS INC does
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for cancer and inflammatory diseases. The company leverages its proprietary DEL-AI platform, combining AI-integrated discovery with advanced chemistry synthesis and direct-to-biology technologies, to develop protein degraders and degrader antibody conjugates (DACs). Its pipeline includes clinical-stage programs targeting BTK (Bruton's tyrosine kinase) for B-cell malignancies and CBL-B inhibitors for immuno-oncology, with collaboration agreements for co-development with Gilead, Sanofi, and Pfizer.
Themes: targeted protein degradation, AI-driven drug discovery, oncology, immunology, precision medicine
Fundamentals
- Price$26.72 as of 2026-08-21 close
- Market cap$2.8B as of 2026-08-21
- 1-year return+176.9% 2025-08-21 close $9.65 → 2026-08-21 close $26.72
- P/En/a negative earnings
- Net margin-928.4% as of 2026-08-24
- ROE-76.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-58.4% as of 2026-08-24
- Revenue CAGR (3y)+29.5% SEC XBRL
- Beta1.80 as of 2026-08-24
- Last reported earnings2026-07-09 SEC EDGAR Form 8-K (Item 2.02)
How NRIX compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NRIX is not currently in any published Top 10 list. Its scores are below.
Long-term score
48.8 #548 of 987 scored · #33 of 57 in Health Care
Financial health 98th (debt to equity 0) and long-term trend 88th (over the past 12 months this stock beat the market by 156.4 percentage points); weakest is profitability (1st, operating margin -982.4%, return on equity -76.1%).
Short-term score
67.7 #20 of 1,704 scored · #8 of 240 in Health Care
Trend 86th: the price is 8% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; momentum 71st: over the past 3 months this stock beat the market by 49.3 percentage points; weakest is setup 45th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 5% of it.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How NURIX THERAPEUTICS INC looks technically
NURIX THERAPEUTICS INC (NRIX) is trading 47.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 177 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 47.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +47.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $23.28 | $23.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $18.14 | $18.14 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 39 calendar days ago — the swings before that are what the structure reading is measured on | 39 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 21.23. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 177 trading days ago — a "golden cross", a bullish long-term signal | 177 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control | 32.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 63.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($23.24 to $28.23) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 69.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $28.23 | $28.23 |
|---|---|---|
| From the 52-week high | it is 5.3% below its 52-week high (its highest price of the past year) | -5.3% |
| Above the 52-week low | it is 226.1% above its 52-week low (its lowest price of the past year) | +226.1% |
| Below the 52-week high | it is 5.3% below its highest point of the past year | 5.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $47.75 (set on 2021-03-16) | $47.75 |
| Given back of the 52-week move | over the past year its closes ranged ($8.24 to $27.79), and it has given back only a small part of its rise from last year’s low — 5% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $15.08 to $15.71. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.5% |
| From the all-time high | it is 44.0% below its all-time high | -44.0% |
| Nearest price level | it is trading 1.3% above a support level at $26.37 — a price it turned at twice since 2024-09-18, most recently on 2024-10-17. Since 2024-08-21 it has 17 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $4.22 (set on 2023-10-26) | $4.22 |
| Above the all-time low | it is 533.2% above its all-time low | +533.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 78% of it) | 78th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.03 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.03 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $22.49 and $28.53 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $22.49 – $25.51 – $28.53 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 8.3 daily ranges above its 200-day average price (47.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.34× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.3% |
|---|---|---|
| Open gap | it gapped 2.1% above the previous close 13 sessions ago and has not traded back through the level it left behind at 23.22 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.1% |
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -3.85% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.5 percentage points (the stock gained 13.8% while the market gained 2.3%) | +11.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 49.3 percentage points (the stock gained 52.4% while the market gained 3.1%) | +49.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 58.3 percentage points (the stock gained 69.3% while the market gained 11.1%) | +58.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 156.4 percentage points (the stock gained 176.9% while the market gained 20.5%) | +156.4% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 25% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.5% of the share price. | +24.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 43% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $18.64 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +43.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-07-09 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $24.71 — a volume-weighted average of daily closes over 32 sessions, not a true tick-by-tick VWAP. | +8.2% |
Price levels it has turned at before
NRIX last closed at $26.72 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $26.37 | Support | 1.3% below the last close | turned there twice · 2024-09-18 to 2024-10-17 |
| $24.98 | Support | 6.5% below the last close | turned there twice · 2026-06-30 to 2026-07-09 |
| $22.98 | Support | 14.0% below the last close | turned there twice · 2024-12-02 to 2024-12-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $21.23.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $32.08 and $38.78 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $21.23.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.44 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$33.50 range $25.00 – $45.00; median $34.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NRIX
- Consensus EPS estimate$5.11 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and uncertainty regarding future profitability.","Dependence on successful clinical trial outcomes and regulatory approvals for drug candidates.","Risks associated with drug development, including potential clinical holds and manufacturing challenges."]
What changed in the latest 10-Q
AI-assisted comparison of NRIX's 10-Q filed 2026-07-09 against the prior one filed 2026-04-08.
Management's Discussion & Analysis (MD&A)
- Added:
- In June 2026, we entered into a global collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (together, Roche), to develop, manufacture, commercialize and otherwise exploit bexobrutideg (NX-5948) (the Roche Collaboration Agreement), which we expect to become effective in the third fiscal quarter of 2026. For more information regarding the Roche Collaboration Agreement, see "Collaboration and License Agreements – Roche" below. [newer filing 2026-07-09]
- Enrollment in the current dose escalation cohorts of the Phase 1 trial has been completed and we are reviewing the data to determine next steps. [newer filing 2026-07-09]
- Removed:
- Seagen Inc. (now a part of Pfizer Inc. (Pfizer)) [removed in newer filing 2026-07-09 and replaced with just Pfizer Inc. (Pfizer)]
- In aggregate, we have received $487.0 million in non-dilutive financing from our collaborators to date and, as of February 28, 2026, we are eligible to receive up to $6.1 billion in potential future fees and milestone payments, as well as royalties on future product sales. We retain certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates, pursuant to these collaborations. [older filing 2026-04-08]
- Reworded:
- "we have built a significant advantage in translating the science of protein degradation into clinical advancements" changed to "we hold a differentiated position in translating the science of protein degradation into clinical advancements" [2026-04-08 to 2026-07-09]
- Pfizer reference: older text stated "Seagen Inc. (now a part of Pfizer Inc. (Pfizer))" in older filing; newer filing only references "Pfizer Inc. (Pfizer)" without the Seagen parenthetical [2026-04-08 to 2026-07-09]
- Collaboration financing information relocated/rewritten: older filing contained specific dollar amounts ($487.0 million received and $6.1 billion potential); newer filing text appears truncated at "$489.0 mill" with different presentation structure [2026-04-08 to 2026-07-09]
- Notes:
- The newer filing text is truncated at the end ('$489.0 mill'), making full comparison of the Drug Discovery Pipeline section impossible
- The older filing text also appears to end mid-sentence ('Collaborations and License Agreements Gilead In June 2019...'), limiting complete comparison
Risk Factors
- Reworded:
- Net loss period changed from '$87.2 million for the three months ended February 28, 2026' (older filing) to '$176.7 million for the six months ended May 31, 2026' (newer filing)
- Accumulated deficit date and amount changed from 'As of February 28, 2026, we had an accumulated deficit of $1.1 billion' (older filing) to 'As of May 31, 2026, we had an accumulated deficit of $1.2 billion' (newer filing)
- Page number changed from '35' (older filing) to '37' (newer filing)
- Notes:
- Both filings appear truncated at the end of the final paragraph; comparison limited to complete text available
- Changes reflect updated financial reporting period (six months ended May 31, 2026 in newer filing versus three months ended February 28, 2026 in older filing) rather than substantive revision to risk factor language
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 13 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 9 sells ($953821) — 3 selling insiders
- Last 90 days0 buys · 13 sells ($2M) — 3 selling insiders
- Last 180 days0 buys · 20 sells ($3M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NRIX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding NRIX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 22,827,543
- Reported value $353,826,926
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NRIX had 18,351,438 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NRIX had 17.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 17.99 days to cover at the same settlement.
- Reported short interest (shares) 18,351,438
- Short interest (% of shares outstanding) 17.7%
- Prior settlement (shares) 17,979,165
- Reported change 2.07%
- Days to cover (reported) 17.99
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Arvinas (ARVN)
- Kymera Therapeutics (KYMR)
- C4 Therapeutics (CCCC)
- Monte Rosa Therapeutics (GLUE)
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NRIX vs…
NURIX THERAPEUTICS INC is found in…
NRIX shows up in…
Frequently asked questions
What does NURIX THERAPEUTICS INC (NRIX) do?
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for cancer and inflammatory diseases. The company leverages its proprietary DEL-AI platform, combining AI-integrated discovery with advanced chemistry synthesis and direct-to-biology technologies, to develop protein degraders and degrader antibody conjugates (DACs).
What sector is NURIX THERAPEUTICS INC (NRIX) in?
NURIX THERAPEUTICS INC (NRIX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are NURIX THERAPEUTICS INC's (NRIX) competitors?
Notable peers of NURIX THERAPEUTICS INC (NRIX) include Arvinas, Kymera Therapeutics, C4 Therapeutics, Monte Rosa Therapeutics and Amgen. This peer set is informational only — not financial advice.
Is NURIX THERAPEUTICS INC (NRIX) overbought or oversold right now?
NURIX THERAPEUTICS INC (NRIX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NRIX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.